{
  "id": "601c46f61cb411341a00001d",
  "type": "yesno",
  "question": "Was golimumab tested for diabetes?",
  "ideal_answer": "Yes, among children and young adults with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin production and less exogenous insulin use than placebo.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33207093"
  ],
  "snippets": [
    {
      "text": "CONCLUSIONS: Among children and young adults with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin production and less exogenous insulin use than placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207093",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "lticenter, placebo-controlled, double-blind, parallel-group trial, we randomly assigned, in a 2:1 ratio, children and young adults (age range, 6 to 21 years) with newly diagnosed overt type 1 diabetes to receive subcutaneous golimumab or placebo for 52 weeks. The primary end point was e",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207093",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}